What is Axsome Therapeutics's free cash flow?

Axsome Therapeutics (AXSM) reported free cash flow of -$20.82M in Q1 2026.

How has Axsome Therapeutics's free cash flow changed year-over-year?

Axsome Therapeutics's free cash flow increased by 52.4% year-over-year, from -$43.71M to -$20.82M.

What is the long-term trend for Axsome Therapeutics's free cash flow?

Over 4 years (2021 to 2025), Axsome Therapeutics's free cash flow has grown at a -3.3% compound annual growth rate (CAGR), from -$108.53M to -$94.87M.

Axsome Therapeutics AXSM Free cash flow

Free cash flow at other companies

Eli LillyLLY

$3.01B+1,828%

Johnson & JohnsonJNJ

$1.47B-56.6%

AbbVieABBV

$3.56B+155%

BridgeBio PharmaBBIO

——

Neurocrine BiosciencesNBIX

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

See full

Revenue$191.2M+57.4%

Gross profit$176.5M+58.0%

Operating income-$63.4M-11.2%

Net income-$64.5M-8.6%

EPS (diluted)-$1.26-3.3%

Balance sheet

See full

Cash & equivalents$305.1M+1.4%

Total debt$219.9M+4.1%

Total equity$54.6M+2.6%

Total assets$713.6M+19.6%

Cash flow

See full

Operating cash flow-$20.7M+52.3%

CapEx$121.0K-64.2%

Valuation

See full

Market cap$12.89B+52.0%

Enterprise value$12.81B+52.9%

P/S18.2×-1.4×

Profitability

See full

Gross margin92.6%+1.1pp

Operating margin-24.4%-9.3pp

Net margin-26.6%-9.8pp

FCF margin-10.2%-3.9pp

Returns & leverage

See full

Return on equity-349.4%+109pp

Debt / equity4×+0.1×

Current ratio1.4×-0.6×

Where this comes from

Calculated from Axsome Therapeutics’s reported figures.

−$20.7Mnet cash from operating−$121.0Kcapital expenditures=-$20.82M

The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Axsome Therapeutics's free cash flow?: Axsome Therapeutics (AXSM) reported free cash flow of -$20.82M in Q1 2026.
How has Axsome Therapeutics's free cash flow changed year-over-year?: Axsome Therapeutics's free cash flow increased by 52.4% year-over-year, from -$43.71M to -$20.82M.
What is the long-term trend for Axsome Therapeutics's free cash flow?: Over 4 years (2021 to 2025), Axsome Therapeutics's free cash flow has grown at a -3.3% compound annual growth rate (CAGR), from -$108.53M to -$94.87M.